Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2024
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over ID 6448Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC